← Eichor
Study identifier: NCT06372899 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Noncombustible Nicotine Delivery Systems as Potential Harm Reduction Tools for Persistent Cigarette Smokers

Condition: E-cigarette Use · Cigarette Smoking · Harm Reduction  ·  Sponsor: Abramson Cancer Center at Penn Medicine

PhaseNA
Planned participants200
Who can joinAll sexes, 21 Years to no upper limit
Healthy volunteersYes

About this study

This between-subjects study aims to evaluate whether e-cigarettes (ECIGS) versus oral nicotine pouches (ONPS) more readily substitute for combustible cigarettes among 200 cigarette smokers. After measuring baseline cigarette smoking rate, participants will be randomized to ECIGS or ONPS and be instructed to switch (versus smoking cigarettes) over a 6-week period. Relative reductions in biomarkers of exposure will be measured. ECIG- and ONP-associated subjective reward and the reinforcing value of ECIGS and ONPS relative to combustible cigarettes will be assessed as mechanisms.

This description comes directly from the study's public registry record.

Talk to the study team

Janet Audrain-McGovern, Ph.D.  ·  215-746-7145  ·  audrain@pennmedicine.upenn.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06372899